NASDAQ:BOLD - Audentes Therapeutics News Headlines

Sign in or create an account to add this stock to your watchlist.
$24.56 +0.25 (+1.03 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$24.56
Today's Range$23.94 - $24.83
52-Week Range$17.95 - $46.18
Volume652,007 shs
Average Volume636,556 shs
Market Capitalization$1.04 billion
P/E Ratio-7.22
Dividend YieldN/A
Beta1.76

Headlines

Audentes Therapeutics (NASDAQ BOLD) News Headlines

Source:
DateHeadline
Audentes Therapeutics Inc (BOLD) Expected to Announce Earnings of -$0.92 Per ShareAudentes Therapeutics Inc (BOLD) Expected to Announce Earnings of -$0.92 Per Share
www.americanbankingnews.com - January 15 at 5:10 PM
HC Wainwright Reiterates "Buy" Rating for Audentes Therapeutics (BOLD)HC Wainwright Reiterates "Buy" Rating for Audentes Therapeutics (BOLD)
www.americanbankingnews.com - January 11 at 11:43 AM
Audentes Therapeutics (BOLD) Raised to Buy at GuggenheimAudentes Therapeutics (BOLD) Raised to Buy at Guggenheim
www.americanbankingnews.com - January 11 at 8:37 AM
Financial Review: Audentes Therapeutics (BOLD) vs. Acorda Therapeutics (ACOR)Financial Review: Audentes Therapeutics (BOLD) vs. Acorda Therapeutics (ACOR)
www.americanbankingnews.com - January 9 at 11:18 PM
Audentes Therapeutics (BOLD) Presents At 37th Annual J.P. Morgan Healthcare Conference - SlideshowAudentes Therapeutics (BOLD) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 9 at 5:18 PM
Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key PrioritiesAudentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities
finance.yahoo.com - January 7 at 9:43 AM
Contrasting Audentes Therapeutics (BOLD) and AVITA MED LTD/S (AVMXY)Contrasting Audentes Therapeutics (BOLD) and AVITA MED LTD/S (AVMXY)
www.americanbankingnews.com - January 6 at 7:32 PM
Audentes Therapeutics appoints Eric B. Mosbrooker as Chief Commercial OfficerAudentes Therapeutics appoints Eric B. Mosbrooker as Chief Commercial Officer
seekingalpha.com - January 3 at 10:01 AM
Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial OfficerAudentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer
finance.yahoo.com - January 3 at 10:01 AM
Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare ConferenceAudentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 9:40 AM
Louis G. Lange Sells 32,000 Shares of Audentes Therapeutics Inc (BOLD) StockLouis G. Lange Sells 32,000 Shares of Audentes Therapeutics Inc (BOLD) Stock
www.americanbankingnews.com - December 27 at 7:28 PM
Audentes Therapeutics Inc (BOLD) Given Consensus Rating of "Hold" by BrokeragesAudentes Therapeutics Inc (BOLD) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 27 at 1:52 AM
Need To Know: Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insiders Have Been Selling SharesNeed To Know: Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insiders Have Been Selling Shares
finance.yahoo.com - December 21 at 4:24 PM
Edited Transcript of BOLD earnings conference call or presentation 6-Nov-18 9:30pm GMTEdited Transcript of BOLD earnings conference call or presentation 6-Nov-18 9:30pm GMT
finance.yahoo.com - November 16 at 4:26 PM
These Biopharmas Could Cure Genetic Diseases — At $5 Million ApieceThese Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
finance.yahoo.com - November 12 at 4:15 PM
Audentes down 21% after Q3 report and pipeline updateAudentes down 21% after Q3 report and pipeline update
seekingalpha.com - November 7 at 4:19 PM
Audentes Therapeutics misses by $0.09Audentes Therapeutics misses by $0.09
seekingalpha.com - November 7 at 9:54 AM
Audentes Therapeutics (BOLD) Misses Q3 EPS by 9cAudentes Therapeutics (BOLD) Misses Q3 EPS by 9c
www.streetinsider.com - November 7 at 9:54 AM
Audentes Therapeutics (BOLD) CEO Matt Patterson on Q3 2018 Results - Earnings Call TranscriptAudentes Therapeutics (BOLD) CEO Matt Patterson on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 9:54 AM
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateAudentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - November 6 at 4:12 PM
Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as ChairmanAudentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman
finance.yahoo.com - November 5 at 10:14 AM
Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018
finance.yahoo.com - October 30 at 4:13 PM
Notable Thursday Option Activity: USB, BOLD, SLBNotable Thursday Option Activity: USB, BOLD, SLB
www.nasdaq.com - October 11 at 4:02 PM
Audentes Therapeutics prices common stock offeringAudentes Therapeutics prices common stock offering
seekingalpha.com - October 11 at 9:19 AM
Audentes Therapeutics Announces Pricing of Public Offering of Common StockAudentes Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 11 at 9:19 AM
Audentes Therapeutics (BOLD) Plans $150M Offering of Common StockAudentes Therapeutics (BOLD) Plans $150M Offering of Common Stock
www.streetinsider.com - October 10 at 9:34 AM
Your Daily Pharma Scoop: Karyopharms NDA Accepted, Audentes Data PositiveYour Daily Pharma Scoop: Karyopharm's NDA Accepted, Audentes Data Positive
seekingalpha.com - October 8 at 4:01 PM
Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%
www.zacks.com - October 8 at 4:01 PM
Audentes Therapeutics to provide update on interim data from ASPIRO trialAudentes Therapeutics to provide update on interim data from ASPIRO trial
seekingalpha.com - October 5 at 4:04 PM
Audentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annual Congress of the World Muscle SocietyAudentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annual Congress of the World Muscle Society
finance.yahoo.com - October 5 at 9:35 AM
Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle SocietyAudentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle Society
finance.yahoo.com - October 5 at 9:35 AM
Audentes Therapeutics (BOLD) to Present New Data from ASPIRO at WMSAudentes Therapeutics (BOLD) to Present New Data from ASPIRO at WMS
www.streetinsider.com - September 24 at 4:05 PM
Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle SocietyAudentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Society
finance.yahoo.com - September 24 at 9:47 AM
Commit To Purchase Audentes Therapeutics At $30, Earn 12.2% Annualized Using OptionsCommit To Purchase Audentes Therapeutics At $30, Earn 12.2% Annualized Using Options
www.nasdaq.com - September 19 at 4:30 PM
Analysts Remain Bullish on BioMarin PharmaceuticalAnalysts Remain Bullish on BioMarin Pharmaceutical
finance.yahoo.com - September 14 at 4:04 PM
Analyzing Audentes Therapeutics’ Valuation MetricsAnalyzing Audentes Therapeutics’ Valuation Metrics
finance.yahoo.com - September 13 at 4:02 PM
Audentes Therapeutics (BOLD) Shares Cross Below 200 DMAAudentes Therapeutics (BOLD) Shares Cross Below 200 DMA
www.nasdaq.com - September 7 at 4:04 PM
B. Riley FBR bearish on Audentes, sees 46% downside riskB. Riley FBR bearish on Audentes, sees 46% downside risk
seekingalpha.com - September 7 at 4:04 PM
Cowen bearish on Audentes, sees 46% downside riskCowen bearish on Audentes, sees 46% downside risk
seekingalpha.com - September 7 at 9:39 AM
Audentes Therapeutics to Participate in Upcoming Investor ConferencesAudentes Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - August 29 at 10:06 AM
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive OfficerE-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
www.bizjournals.com - August 23 at 9:44 AM
Audentes gene therapy AT132 nabs special FDA designation for rare muscle weakness disorderAudentes gene therapy AT132 nabs special FDA designation for rare muscle weakness disorder
seekingalpha.com - August 21 at 9:50 AM
Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular MyopathyAudentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy
finance.yahoo.com - August 21 at 9:50 AM
Edited Transcript of BOLD earnings conference call or presentation 7-Aug-18 12:00pm GMTEdited Transcript of BOLD earnings conference call or presentation 7-Aug-18 12:00pm GMT
finance.yahoo.com - August 20 at 10:08 AM
Audentes Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare ConferenceAudentes Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 9 at 10:06 AM
Backed with $140M, startup launches three-pronged attack on liver diseasesBacked with $140M, startup launches three-pronged attack on liver diseases
finance.yahoo.com - August 8 at 4:05 PM
Audentes Therapeutics (BOLD) CEO Matt Patterson on Q2 2018 Results - Earnings Call TranscriptAudentes Therapeutics (BOLD) CEO Matt Patterson on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 4:02 PM
Audentes Therapeutics: 2Q Earnings SnapshotAudentes Therapeutics: 2Q Earnings Snapshot
finance.yahoo.com - August 7 at 10:06 AM
Audentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular MyopathyAudentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular Myopathy
finance.yahoo.com - July 31 at 10:02 AM
Is Audentes Therapeutics (BOLD) Stock Outpacing Its Medical Peers This Year?Is Audentes Therapeutics (BOLD) Stock Outpacing Its Medical Peers This Year?
finance.yahoo.com - July 20 at 4:02 PM
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Featured Article: How mutual funds make money

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel